Antibody-based therapies for cancer rely on the expression of defined antigens on neoplastic cells . The goal of this approach to cancer therapy is to concentrate the cytokine in the tumour microenvironment and thereby stimulate cellular T cell, B-cell, or NK immune responses against malignancies. In the past decade, multiple antibody-cytokine fusion proteins have been developed with different specificities targeting a broad variety of tumours. These novel molecules retain both antibody and cytokine associated functions and have been effective in eradicating established metastases in neuroblastomas, melanomas, and hepatic and pulmonary carcinomas in mouse models.
Efficacy appears to be greatest when the mAb can recruit the effector cells of the host’s immune system into helping in the mediation of the anti tumour effect . In animals bearing malignancies, antibody-cytokine fusion proteins are able to elicit a significant antitumour response that in some cases results in a complete elimination of the tumour. You will always find best quality drugs ever, because now you can enjoy your shopping every time you need zoloft for depression with a nice discount and delivery straight to your home, being sure this is the exact treatment your condition requires.
Current research in immunocytokines suggests that antibody-cytokine fusion proteins using IL-2 may have potential for use in the treatment of human colon cancer. Fusion protein-directed IL-2 therapy induces a T cell-dependent host immune response capable of eradicating established metastatic lesions of the colon in animal tumour models. When IL-2 fusion proteins constructed of a tumour-specific antibody joined to IL-2 were used to deliver cytokine directly to the site of tumour cells in vivo, the protein was found to augment lysis of tumour cells. Analysis of the mechanism of cytotoxicity revealed that the fusion protein mediates the formation of stable conjugates between T cells expressing IL-2R and tumour cells expressing the specific antigen, resulting in lysis through the Fas-Fas ligand pathway.